Products Categories
CAS No.: | 120066-54-8 |
---|---|
Name: | Gadoteridol |
Article Data: | 3 |
Molecular Structure: | |
Formula: | C17H29GdN4O7 |
Molecular Weight: | 558.69 |
Synonyms: | Gadolinium,[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-N1,N4,N7,N10,O1,O4,O7,O10]-;1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-(2-hydroxypropyl)-,gadolinium complex;(10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato)gadolinium;Gadolinium-HP-DO 3A;ProHance;SQ 32692; |
EINECS: | 1533716-785-6 |
Melting Point: | >225oC |
Boiling Point: | 668.2 °C at 760 mmHg |
Flash Point: | 357.9 °C |
Hazard Symbols: | Xn,T,N,Xi |
Risk Codes: | 22-25-36-50-43-41 |
Safety: | 45-26-61-36/37-39 |
PSA: | 101.09000 |
LogP: | -2.14850 |
gadoteridol
Conditions | Yield |
---|---|
In water at 85℃; | 99% |
gadoteridol
Conditions | Yield |
---|---|
With hydrogenchloride In water at 20℃; for 12h; pH=4 - 6.5; Inert atmosphere; | 25% |
gadolinium(III) chloride
gadoteridol
Conditions | Yield |
---|---|
In water Kinetics; in lightly buffered medium (sodium acetate/acetic acid), 25.0°C +/- 0.1°C, ionic strength 1.0 (NaCl); not isolated; monitoring by UV; |
Molecular Structure of Gadoteridol (CAS NO.120066-54-8):
IUPAC Name: Gadolinium(3+); 2-[4-(2-hydroxypropyl)-7,10-bis(2-oxido-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate
Molecular Formula: C17H29GdN4O7
Molecular Weight: 558.68
Flash Point: 357.9 °C
Enthalpy of Vaporization: 112.4 kJ/mol
Boiling Point: 668.2 °C at 760 mmHg
Vapour Pressure: 1.04E-20 mmHg at 25 °C
Classification Code: Contrast media; Diagnostic aid [paramagnetic]; Drug / Therapeutic Agent
SMILES: [Gd+3].[O-]C(=O)CN1CCN(CCN(CCN(CC(O)C)CC1)CC([O-])=O)CC([O-])=O
InChI: InChI=1/C17H32N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26;/h14,22H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3
InChIKey: DPNNNPAKRZOSMO-DFZHHIFOAX
Gadoteridol (CAS NO.120066-54-8) is used in the imaging of the central nervous system. A research shows that high-dose gadoteridol study may facilitate the care of patients with suspected central nervous system metastasis.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | intravenous | > 2800mg/kg (2800mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 36, Pg. 1409, 1994. | |
mouse | LD50 | intravenous | 6146mg/kg (6146mg/kg) | Drugs of the Future. Vol. 17, Pg. 187, 1992. | |
rat | LD | intravenous | > 5587mg/kg (5587mg/kg) | Drugs of the Future. Vol. 17, Pg. 187, 1992. |
Gadoteridol (CAS NO.120066-54-8), its Synonyms are (+-)-(10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-))gadolinium ; (10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato)gadolinium ; GD-HP-DO 3A ; Gadolinium, (10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-N(sup 1),N(sup 4),N(sup 7),N(sup 10),O(sup 1),O(sup 4),O(sup 7),O(sup 10))- ; Gadolinium-HP-DO3A ; Gadolinium-HP-Do 3A ; Gadoteridolum . It is a magnetic resonance contrast agent.